Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadian Patents |
| October 13, 2021 | October 2021 Bond Updates |
|
LONDON, Oct. 13, 2021 /PRNewswire/ -- Actimed Therapeutics Ltd, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, announces that it has been granted a United States patent for ACM-001 (S-pindolol) for treating... |
| View more at: https://www.prnewswire.com:443/news-releases/actimed-therapeutics-continues-to-strengthen-intellectual-property-portfolio-with-newly-granted-us-and-canadian-patents-301398462.html |
| Related News |
|